Recombinant VEGF (Ranibizumab Biosimilar) antibody

Catalog No. ABIN7200657

The Mouse Monoclonal anti-VEGF (Ranibizumab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect VEGF (Ranibizumab Biosimilar) in samples from Human.

Quick Overview for Recombinant VEGF (Ranibizumab Biosimilar) antibody (ABIN7200657)

Target: VEGF (Ranibizumab Biosimilar)

Antibody Type: Recombinant Antibody

Fragment: Fab fragment

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This VEGF (Ranibizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Product Details anti-VEGF (Ranibizumab Biosimilar) Antibody

Purpose: Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)

Specificity: The Fab protein ranibizumab specifically binds to the human VEGF-A.

Characteristics: Recombinant Humanized Monoclonal Antibody Fragment (Fab) generated from the same parent mouse antibody as bevacizumab.

Purification: Protein A affinity column

Purity: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The research grade Fab protein ranibizumab was produced in the ranibizumab biosimilar E.coli cell line.

Application Details

Application Notes: Functional assay, neutralization.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Handling Advice: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months

Target Details for VEGF (Ranibizumab Biosimilar)

Target: VEGF (Ranibizumab Biosimilar)

Target Type: Biosimilar

Background: The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.

Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.